The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
News|Articles|August 27, 2007
Access to acute anemia agent under study may be expanded
Biopure Corp. has drafted a protocol for patients with life-threatening anemia for whom blood transfusion is not feasible to obtain its investigational product Hemopure (HBOC-201) on a compassionate-use basis.
Advertisement
Access to acute anemia agent under study may be expanded Biopure Corp. has drafted a protocol for patients with life-threatening anemia for whom blood transfusion is not feasible to obtain its investigational product Hemopure (HBOC-201) on a compassionate-use basis. The draft protocol lists the eligibility criteria for patients. The Cambridge, Mass., firm is awaiting word from the FDA to its draft protocol.
Advertisement
Related to this article
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
3
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
4
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
5